@KimmelmanJ Some more digging on this point led to this @asjrodriguez RL showing lower net prices following biologic competitor entry, though in some cases the decreases began even before entry:https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2757480 …
-
-
-
Also found this via AHIP which shows higher % rebates among branded competition. Dumb Q, but hypothetically could lockstep increases in list price result in stable net prices? Is there more documentation of lower net prices other than the prior RL I'm not aware of? (New to this.)pic.twitter.com/1nSMP3yxZK
- Još 2 druga odgovora
Novi razgovor -
-
-
The 1st generic in a class doesn't necessarily move the needle much, but adding a 2nd, 3rd, 4th, etc. certainly does. Until a few years ago the U.S. generics market behaved very well, with significant price drops following patent expiry. Recently, we've seen a few hitches.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
But higher list prices, which means folks without insurance or who are enrolled in high deductible plans with higher copayments for pharmacy benefits pay more, no?
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
